Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Leucyl-L-Isoleucine has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Hydrolysis of the dipeptide delivers free leucine, so the two are the same input arriving by different routes. The dipeptide route uses PEPT1 and can load faster, while free leucine uses amino acid transporters that saturate at high single doses. Anyone counting total leucine in a formula needs to count both.
Valine shares the LAT1 transporter and the branched-chain aminotransferase step with leucine and isoleucine. Loading leucine and isoleucine without valine drives valine levels down over time, which is the reason branched-chain products are conventionally balanced rather than leucine-only. This is a ratio question, not a dose question.
The first committed step in disposing of leucine and isoleucine cannot run without PLP. If the cofactor is short, the transamination step limits how fast a branched-chain load clears. This is a requirement for normal metabolism, not a reason to expect a benefit from extra B6 in someone whose status is already adequate.
The second step of branched-chain catabolism, oxidative decarboxylation of the keto acids, depends on thiamine pyrophosphate along with lipoate, FAD and NAD. Without it the keto acids accumulate rather than being oxidised. This is textbook pathway biochemistry and applies to any branched-chain amino acid load.
FAD is required at several points after the keto acids are decarboxylated. Riboflavin status therefore sits underneath branched-chain oxidation in the same way it sits underneath fatty acid oxidation. It is a permissive requirement rather than a lever to push.
A small fraction of leucine is converted through alpha-ketoisocaproate to HMB. Supplying leucine, whether free or peptide-bound, increases the substrate available for that conversion, though the conversion rate is low and variable. Taking both means one input arrives as precursor and one already downstream of the conversion step.
Taking a fast-absorbing dipeptide alongside casein blunts the speed advantage, because gastric emptying then governs delivery for both. If the point of using a peptide form is a rapid rise in plasma branched-chain amino acids, pairing it with a slow protein works against that. This is a formulation timing issue rather than a chemical interaction.
Nothing specific on file for Leucyl-L-Isoleucine. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.